Vir Biotechnology Inc VIR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026
-
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2026 Financial Results
-
Vir Biotechnology to Participate in Bank of America Securities 2026 Healthcare Conference
-
Vir Biotechnology to Host Conference Call for First Quarter 2026 Financial Results
-
Vir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatment of Prostate Cancer
-
Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN® Dual-masked T-cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer
-
Vir Biotechnology, Astellas in $335 Million Licensing Deal for Prostate Cancer Treatment
Trading Information
- Previous Close Price
- $8.51
- Day Range
- $8.17–8.72
- 52-Week Range
- $4.16–11.65
- Bid/Ask
- $8.26 / $8.28
- Shares Outstanding
- 168.65M
- Market Cap
- $1.39B
- Volume/Avg
- 847,926 / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 18.54
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 367
- Website
- https://www.vir.bio
Valuation
|
Metric
|
VIR
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.69 |
Price/Sales | 18.54 |
Price/Cash Flow | — |
Price/Earnings
VIR
Financial Strength
|
Metric
|
VIR
|
|---|---|
Quick Ratio | 6.48 |
Current Ratio | 7.11 |
Interest Coverage | — |
Quick Ratio
VIR
Profitability
|
Metric
|
VIR
|
|---|---|
Return on Assets (Normalized) | −36.21% |
Return on Equity (Normalized) | −46.02% |
Return on Invested Capital (Normalized) | −44.22% |
Return on Assets
VIR
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Hsrhzhfr | Pfrrgd | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Ybvkmchj | Xyfmsz | $65B | |||
| argenx SE ADR
ARGX
| Zgcjwrvvx | Jtr | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Bnfnkppq | Vgyqzb | $40B | |||
| Royalty Pharma PLC Class A
RPRX
| Nzkcsmkqmj | Dhxxvvt | $25B | |||
| BioNTech SE ADR
BNTX
| Nykqjwprr | Lgn | $22B | |||
| Incyte Corp
INCY
| Qtcvbvlx | Pcmk | $21B | |||
| Moderna Inc
MRNA
| Zsrjnhnn | Hnb | $19B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Cwvwqnpx | Kdsz | $14B | |||
| BridgeBio Pharma Inc
BBIO
| Bpstcyz | Xwzyd | $13B |
United States